• Pfizer's Migraine Drug Approval Triggers $475M Payment to Royalty Pharma

    12 days ago - By MedCity News

    Royalty Pharma's milestone payment from the approval of Pfizer migraine drug Zavzpret stems from financing deals struck with the therapy's previous developer, Biohaven Pharmaceuticals. Royalty Pharma is also in line to receive royalty payments going beyond the next decade.
    Read more ...